drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Chimeric IgG1 monoclonal antibody targeting TNF-α; binds soluble and transmembrane TNF-α to block TNFR1/TNFR2 signaling, suppress NF-κB–mediated pro-inflammatory cytokines, and can induce apoptosis and CDC/ADCC of TNF-expressing cells. Includes subcutaneous biosimilar CT-P13.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous, Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds and neutralizes soluble and transmembrane TNF-alpha, blocking TNFR1/TNFR2 signaling, reducing NF-kappaB-driven pro-inflammatory cytokines and leukocyte recruitment; can induce apoptosis and CDC/ADCC of TNF-expressing cells. Includes subcutaneous biosimilar CT-P13.
drug_name
Infliximab
nct_id_drug_ref
NCT06113913